Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALPP ASPIRE-T
- Development stage
- Preclinical
- Lead developer
- TCRCure Biotech
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
ALPP ASPIRE-T is an investigational cell therapy developed by TCRCure Biotech for the treatment of gynecological and lung cancers. It is built on TCRCure's proprietary ASPIRE-T platform, a next-generation T cell therapy platform designed to redirect the TCR/CD3 complex. This approach aims to overcome the limitations of conventional CAR-T and TCR-T therapies, delivering robust, sustained, and safer immune responses against solid tumors by targeting placental alkaline phosphatase (ALPP), an oncofetal antigen highly expressed in various solid tumors but restricted in normal adult tissues.
02
Targets
ALPP (Alkaline phosphatase, placental type)
Beyond the preview
Go deeper on ALPP ASPIRE-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALPP ASPIRE-T.